SPECIAL ARTICLE

European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update

M. Rouprêt, R. Zigeuner, J. Palou, A. Boehle, E. Kaasinen, R. Sylvester, M. Babjuk, W. Oosterlinck

a Departamento de Urología, Pitié-Salpêtrière Hospital, GHU Est, Assistance-Publique Hôpitaux de Paris, Facultad de Medicina Pierre et Marie Curie, Universidad Paris VI, París, France
b Departamento de Urología, Universidad de Mediciona de Graz, Graz, Austria
c Departamento de Urología, Fundación Puigvert, Barcelona, Spain
d Servicio de Urología, Hospital HELIOS Agnes Karll, 23611 Bad Schwartau, Germany
e Servicio de Urología, Hospital Hyvinkää, Hysinkää, Finland
f Organización Europea para la Investigación y el Tratamiento del Cáncer, Departamento de Bioestadística, Bruselas, Belgium
g Servicio de Urología, Hospital Motol, Segunda Facultad de Medicina, Universidad Charles, Praga, Czech Republic
h Servicio de Urología, Hospital Universitario Ghent, Belgium

Received 12 September 2011; accepted 12 September 2011
Available online 21 March 2012

KEYWORDS
Guidelines; Urothelial carcinoma; Prognosis; Urinary markers; Renal pelvis; Ureter; Laparoscopy; Ureteroscopy; Nephroureterectomy

Abstract
Context: The European Association of Urology (EAU) Guideline Group for urothelial cell carcinoma of the upper urinary tract (UUT-UCC) has prepared new guidelines to aid clinicians in assessing the current evidence-based management of UUT-UCC and to incorporate present recommendations into daily clinical practice.
Objective: This paper provides a brief overview of the EAU guidelines on UUT-UCC as an aid to clinicians in their daily practice.
Evidence acquisition: The recommendations provided in the current guidelines are based on a thorough review of available UUT-UCC guidelines and papers identified using a systematic search of Medline. Data on urothelial malignancies and UUT-UCCs in the literature were searched using Medline with the following keywords: urinary tract cancer, urothelial carcinomas, upper urinary tract, carcinoma, transitional cell, renal pelvis, ureter, bladder cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. A panel of experts weighted the references.

* Corresponding author.
E-mail address: morgan.roupret@psl.aphp.fr (M. Rouprêt).

2173-5786/$ - see front matter © 2011 AEU. Published by Elsevier España, S.L. All rights reserved.
**Evidence synthesis:** There is a lack of data in the current literature to provide strong recommendations due to the rarity of the disease. A number of recent multicentre studies are now available, whereas earlier publications were based only on limited populations.

However, most of these studies have been retrospective analyses. The 2009 TNM classification is recommended. Recommendations are given for diagnosis as well as for radical and conservative treatment; prognostic factors are also discussed. Recommendations are provided for patient follow-up after different therapeutic options.

**Conclusions:** These guidelines contain information for the diagnosis and treatment of individual patients according to a current standardised approach. When determining the optimal treatment regimen, physicians must take into account each individual patient’s specific clinical characteristics with regard to renal function including medical comorbidities, tumour location, grade and stage, and molecular marker status.

© 2011 AEU. Published by Elsevier España, S.L. All rights reserved.

---

**PALABRAS CLAVE**

Guías; Carcinoma urotelial; Pronóstico; Marcadores urinarios; Pelvis renal; Uréter; Laparoscopía; Ureteroscopía; Nefroureterectomía

---

**Guía clínica para el diagnóstico y tratamiento de los carcinomas de las células uroteliales de las vías urinarias superiores: actualización de 2011**

**Resumen**

**Contexto:** El Grupo de Guías Clínicas sobre el carcinoma de células uroteliales de las vías urinarias superiores (CCU-VUS) de La Asociación Europea de Urología (EAU) ha elaborado una nueva guía clínica para ayudar a los médicos a evaluar el tratamiento del CCU-VUS basado en los datos científicos, y a incorporar las presentes recomendaciones a la práctica clínica diaria.

**Objetivo:** Este documento ofrece una breve visión general de la guía clínica de la EAU sobre el CCU-VUS como una ayuda para los médicos en su práctica diaria.

**Adquisición de datos científicos:** Las recomendaciones proporcionadas en la guía actual se basan en una metelesa revisión de las guías y documentos sobre CCU-VUS disponibles, identificados mediante una búsqueda sistemática en Medline. Los datos sobre neoplasias uroteliales malignas y CCU-VUS en la literatura se buscaron mediante Medline con las siguientes palabras clave: cáncer del tracto urinario, carcinomas uroteliales, tracto urinario superior, carcinoma, células de transición, pelvis renal, uréter, cáncer vesical, quimioterapia, nefroureterectomía, tratamiento adyuvante, tratamiento neoadyuvante, recidiva, factores de riesgo y supervivencia. Un equipo de expertos sopesó las referencias.

**Síntesis de los datos científicos:** Hay una falta de datos en la literatura actual para proporcionar recomendaciones consistentes, debido a la rareza de la enfermedad. Una serie de recientes estudios multicéntricos ya están disponibles, mientras que las publicaciones anteriores se basaban solo en poblaciones limitadas. Sin embargo, la mayoría de estos estudios han sido análisis retrospectivos. Se recomienda la clasificación TNM2009. Se hacen recomendaciones para el diagnóstico, así como para el tratamiento radical y conservador; también se tratan los factores pronósticos. Se proporcionan recomendaciones para el seguimiento del paciente después de diferentes opciones terapéuticas.

**Conclusions:** Esta guía contiene información para el diagnóstico y tratamiento de los pacientes individuales de acuerdo a un enfoque estándar actual. Al determinar el régimen de tratamiento óptimo, los médicos deben tener en cuenta las características clínicas específicas de cada paciente con respecto a la función renal, incluyendo comorbididades médicas, localización del tumor, grado y estadío y el estado de los marcadores moleculares.

© 2011 AEU. Publicado por Elsevier España, S.L. Todos los derechos reservados.

---

**Introduction**

The most recent summary of the European Association of Urology (EAU) guidelines on upper urinary tract urothelial cell carcinomas (UUT-UCCs) was published in 2004.1 The EAU Guideline Group for UUT-UCCs has prepared the current guidelines to provide evidence-based information for the clinical management of these rare tumours and to help clinicians incorporate these recommendations into their practice. The current update is based on a structured literature search.

---

**Evidence acquisition**

A Medline search was performed on urothelial malignancies and UUT-UCC management using combinations of the following terms: urinary tract cancer, urothelial carcinomas, upper urinary tract, carcinoma, transitional cell, renal pelvis, ureter, bladder cancer, chemotherapy, nephroureterectomy, adjuvant treatment, neoadjuvant treatment, recurrence, risk factors, and survival. The publications concerning UUT-UCCs were mostly retrospective, including some large multicentre studies. Due to the scarcity of randomised data,
articles were selected for these guidelines based on the following criteria: evolution of concepts, intermediate- and long-term clinical outcomes, study quality, and relevance. Older studies were included selectively if they were historically relevant or if data were scarce in recent publications. To facilitate evaluation of the quality of the information provided, levels of evidence (LE) and grades of recommendation (GR) were inserted according to general principles of evidence-based medicine.²

Epidemiology

Urothelial carcinomas are the fourth most common tumors after prostate (or breast) cancer, lung cancer, and colorectal cancer.³,⁴ They can be located in the lower urinary tract (bladder and urethra) or the upper urinary tract (pylecalcal cavities and ureter). Bladder tumors account for 90–95% of urothelial carcinomas⁴ and are the most common malignancy of the urinary tract and the second most common malignancy of the urogenital tract after prostate cancer.⁵,⁶ However, UUT-UCCs are uncommon and account for only 5–10% of urothelial carcinomas.³,⁷⁹ The estimated annual incidence of UUT-UCCs in Western countries is about one or two new cases per 100,000 inhabitants. Pyelocalyceal tumors are about twice as common as ureteral tumors. In 8–13% of cases, concurrent bladder cancer is present. Recurrence of disease in the bladder occurs in 30–51% of UUT-UCC patients,¹⁰,¹¹ whereas recurrences in the contralateral upper tract are observed in 2–6%,¹²,¹³ The natural history of UUT-UCCs differs from that of bladder cancer: 60% of UUT-UCCs are invasive at diagnosis compared with only 15% of bladder tumors.⁵,⁷⁹ UUT-UCCs have a peak incidence in people in their 70s and 80s, and UUT-UCC is three times more prevalent in men than in women.

There are familial/hereditary cases of UUT-UCCs linked to hereditary nonpolyposis colorectal carcinoma (HNPPC).¹⁴ Among patients with UUT-UCCs, these cases can be detected during a medical interview. Indeed, the cancer is likely to be hereditary if the patient is <60 yr of age and/or has a personal or family history of an HNPPC-type cancer.¹⁵,¹⁶ These patients should undergo DNA sequencing to identify hereditary cancers that have been misclassified as sporadic cancers by insufficient clinical data. The presence of other HNPPC-associated cancers should also be evaluated. These patients should be closely monitored, and genetic counseling is advocated.¹⁵,¹⁶

Risk factors

Many environmental factors contribute to the development of UUT-UCCs. Some are similar to those associated with bladder cancer, whereas others are more specific for UUT-UCC. Tobacco and occupational exposure remain the principal exogenous risk factors in the development of these tumors. Exposure to tobacco increases the relative risk of developing a UUT-UCC from 2.5 to 7.¹⁷,¹⁸ UUT-UCC “amino tumours” are related to occupational exposure to certain aromatic amines. These aromatic hydrocarbons are used in many industries (e.g., dyes, textiles, rubber, chemicals, petrochemicals, and coal). They are responsible for the carcinogenicity of certain chemicals, including benzidine and β-naphthalene. These two chemicals have been banned since the 1960s in most industrialised countries. In most cases, UUT-UCCs are secondary to an amino tumour of the bladder. The average duration of exposure needed to develop a UUT-UCC is approximately 7 yr, with a latency period of about 20 yr following the termination of exposure. The estimated risk (odds ratio) of developing UCC after exposure to aromatic amines is 8.3.¹⁷,¹⁹

Upper urinary tract tumors resulting from phenacetin consumption almost disappeared¹⁰ after the product was banned in the 1970s.

Although the incidence of Balkan endemic nephropathy is also on the decline,¹⁰,²¹ roles have been proposed for aristolochic acid and the consumption of Chinese herbs in the physiopathology and induction, respectively, of this nephropathy.¹²–¹⁶ Several studies have revealed the carcinogenic potential of aristolochic acid contained in Aristolochia fangchi and Aristolochia clematitis (plants endemic to the Balkans). This acid contains a set of highly toxic nitrophenolate derivatives that exhibit a powerful mutagenic action due to their ability to make up covalent links with cell DNA. The aristolochic acid derivative d-aristolactam causes a specific mutation in the p53 gene at codon 139. This mutation is very rare in the non-exposed population and is predominant in patients with nephropathy due to Chinese herbs or Balkan endemic nephropathy who present with UUT-UCC.

A high incidence of UUT-UCC has also been described in Taiwan, especially in the population of the southwest coast of the island, and it represents 20–25% of UCCs in the region.¹⁶ The association of UUT-UCC with blackfoot disease and arsenic exposure remains unclear in this patient population.²⁵

Differences in the ability to counteract carcinogens may contribute to host susceptibility and the risk of developing urothelial carcinomas. Because certain genetic polymorphisms are associated with an increased risk of cancer or faster disease progression, there is variability in interindividual susceptibility to the risk factors just mentioned. Only one polymorphism specific to UUT-UCC has been reported so far. A variant allele, SULT1A1*2, which reduces sulfotransferase activity, enhances the risk of developing UUT-UCC.¹⁶ Epidermoid carcinoma of the UUT is associated with chronic inflammatory and infectious disease arising from stones in the UUT.²⁷,²⁸

Histology and classification

Histologic types

More than 95% of urothelial carcinomas are derived from the urothelium and correspond to UUT-UCCs or bladder tumors.¹,²,²⁸ With regard to UUT-UCCs, morphologic variants have been described that are more often observed in urothelial kidney tumors. These variants always correspond to high-grade tumors, and such urothelial carcinomas are associated with one of the following variants: micropapillary, clear cell, neuroendocrine, and lymphoepithelial.⁷,²⁷
Collecting duct carcinoma has similar characteristics to UUT-UCCs because of its common embryologic origin.29

Upper urinary tract tumours with nonurothelial histology are exceptions.30 Epidermoid carcinomas of the upper urinary tract represent <10% of pyelocaliceal tumours and are even more rare within the ureter. Other histologic subtypes are adenocarcinomas (<1%), neuroendocrine carcinomas, and sarcomas.

Classification
The classification and morphology of UUT-UCCs are similar to those of bladder carcinomas.5,28 It is possible to distinguish between non-invasive papillary tumours (papillary urothelial tumours of low malignant potential, low-grade papillary urothelial carcinoma, high-grade papillary urothelial carcinoma), flat lesions (carcinoma in situ (CIS)), and invasive carcinomas. All variants of urothelial tumours described in the bladder can also be observed in the upper urinary tract.

TNM staging. Table 1 presents the Union Internationale Contre le Cancer 2009 TNM classification used throughout these guidelines.31 According to the TNM classification, the regional lymph nodes that should be considered are the hilar, abdominal para-aortic, and paracaval nodes, and, for the ureter, the intrapelvic nodes. Laterality does not affect the N classification.

Tumour grade. Until 2004, the most common classification used was the World Health Organisation (WHO) classification of 1973, which distinguished only three grades (G1, G2, and G3).32 In recent years, molecular biologic data have allowed for further distinction between different tumour groups and the development of a new classification system that better reflects the potential growth of these tumours.33 Thus the 2004 WHO classification now takes histologic data into account to distinguish among three groups of non-invasive tumours: papillary urothelial neoplasia of low malignant potential, low-grade carcinomas, and high-grade carcinomas. There are almost no tumours of low malignant potential in the upper urinary tract.9,27,28

Symptoms
The diagnosis of a UUT-UCC may be fortuitous or related to the exploration of symptoms.1,6 The symptoms are generally restricted.34 The most common symptom of UUT-UCC is gross or microscopic haematuria (70–80%). Flank pain occurs in up to 20–40% of cases, and a lumbar mass is present in 10–20% of cases.1,7 However, systemic symptoms (altered health condition including anorexia, weight loss, malaise, fatigue, fever, night sweats, or cough) associated with UUT-UCC should prompt consideration of a more rigorous metastatic evaluation or perioperative chemotherapy regimen.34

Diagnosis

Imaging
Multidetector computed tomographic urography. Multidetector computed tomographic urography (MDCTU) is the gold standard for exploration of the upper urinary tract and has replaced intravenous excretory urography.35–38 It must be conducted under optimal conditions, particularly with acquisition of an excretory phase. Multiple protocols from two helical computed tomography acquisitions (at least millimetric) are necessary before and after the injection of contrast.

The detection rate of UUT-UCC is satisfactory for this type of imaging: 96% sensitivity and 99% specificity for polypoid lesions between 5 and 10 mm. Sensitivity drops to 89% for polypoid lesions <5 mm and 40% for polypoid lesions <3 mm.16,17 MDCTU can also detect thickening of the wall of the renal pelvis or ureter as a sign of UUT-UCC. The main difficulty remains identifying flat lesions that are undetectable until they evolve towards a massive infiltration.

Lastly, it was shown that hydronephrosis on preoperative imaging was associated with advanced pathologic disease and poorer oncologic outcomes.39

Magnetic resonance imaging. Magnetic resonance imaging (MRI) urography is indicated in patients who cannot be subjected to an MDCTU.40 The detection rate of MRI is 75% after contrast injection for tumours <2 cm.41 Magnetic resonance urography with contrast injection, however, remains contraindicated in selected patients with severe renal impairment (<30 ml/min creatinine clearance) due to the risk of nephrogenic systemic fibrosis. MRI without contrast is less helpful compared with MDCTU in diagnosing UUT-UCCs.

Table 1  TNM classification 2009 for urothelial cell carcinoma of the upper urinary tract.31

<table>
<thead>
<tr>
<th>TNM classification 2009 for urothelial cell carcinoma of the upper urinary tract.31</th>
<th>a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>T</strong> – Primary tumour</td>
<td>All EAU guidelines only advocate the TNM system of tumour classification.</td>
</tr>
<tr>
<td>TX Primary tumour cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>T0 No evidence of primary tumour</td>
<td></td>
</tr>
<tr>
<td>Ta Non-invasive papillary carcinoma</td>
<td></td>
</tr>
<tr>
<td>Tis Carcinoma in situ</td>
<td></td>
</tr>
<tr>
<td>T1 Tumour invades subepithelial connective tissue</td>
<td></td>
</tr>
<tr>
<td>T2 Tumour invades muscularis</td>
<td></td>
</tr>
<tr>
<td>T3 (Renal pelvis) Tumour invades beyond muscularis into peripelvic fat or renal parenchyma</td>
<td></td>
</tr>
<tr>
<td>(Ureter) Tumour invades beyond muscularis into periureteric fat</td>
<td></td>
</tr>
<tr>
<td>T4 Tumour invades adjacent organs or through the kidney into perinephric fat</td>
<td></td>
</tr>
<tr>
<td><strong>N</strong> – Regional lymph nodes</td>
<td></td>
</tr>
<tr>
<td>NX Regional lymph nodes cannot be assessed</td>
<td></td>
</tr>
<tr>
<td>NO Regional lymph node metastasis No regional lymph node metastasis</td>
<td></td>
</tr>
<tr>
<td>N1 Metastasis in a single lymph node 2 cm or less in the greatest dimension</td>
<td></td>
</tr>
<tr>
<td>N2 Metastasis in a single lymph node more than 2 cm but not more than 5 cm in the greatest dimension or multiple lymph nodes, none more than 5 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td>N3 Metastasis in a lymph node more than 5 cm in greatest dimension</td>
<td></td>
</tr>
<tr>
<td><strong>M</strong> – Distant metastasis</td>
<td></td>
</tr>
<tr>
<td>MO No distant metastasis</td>
<td></td>
</tr>
<tr>
<td>M1 Distant metastasis</td>
<td></td>
</tr>
</tbody>
</table>
Cystoscopy and urinary cytology

Positive urine cytology is highly suggestive of UUT-UCC when bladder cystoscopy is normal and if CIS of the bladder or prostatic urethra has been excluded. Cytology is less sensitive for UUT-UCC than for bladder tumours, even for high-grade lesions, and it should ideally be performed in situ (i.e., in the renal cavities). A positive cytology may be valuable in staging because it has been associated with muscle-invasive and non-organ-confined disease.42

The detection of molecular abnormalities by fluorescence in situ hybridisation (FISH) is becoming more popular for UCC screening, but results are still preliminary.43,44 The sensitivity of FISH for the identification of UUT-UCCs parallels its performance in bladder cancer; however, the preponderance of low-grade recurrent disease in the population undergoing surveillance and minimally invasive therapy for UUT-UCCs may limit its usefulness.45 In addition, FISH appears to have limited value for upper urinary tract tumour surveillance.46,47

Diagnostic ureteroscopy

Ureteroscopy is a better approach to diagnose UUT-UCCs.42,48,49 A flexible ureteroscope can explore the ureter macroscopically and reach renal cavities in 95% of cases, and it can assess the aspect of the tumour, obtain tumour biopsy, and determine tumour grade in 90% of cases with a low false-negative rate.50 It also facilitates performing a selective ureteral cytology and a retrograde pyelogram.

Flexible ureteroscopy is especially useful when there is diagnostic uncertainty, when conservative treatment is being considered, or in patients with a solitary kidney. The possible advantages of ureteroscopy should be discussed in the preoperative assessment of any UUT-UCC patient. Combining ureteroscopic biopsy grade, ipsilateral hydronephrosis, and urinary cytology may help decision making on radical nephroureterectomy (RNU) vs endoscopic treatment.42 Table 2 lists the recommendations.

Table 2  Guidelines for the diagnosis of urothelial cell carcinoma of the upper urinary tract.

<table>
<thead>
<tr>
<th>Recommendations for diagnosis of UUT-UCC</th>
<th>GR</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Urinary cytology</td>
<td>A</td>
</tr>
<tr>
<td>• Cystoscopy to rule out a concomitant bladder tumour</td>
<td>A</td>
</tr>
<tr>
<td>• MDCTU</td>
<td>A</td>
</tr>
</tbody>
</table>

chronologic age alone is an inadequate indicator of outcomes in older UUT-UCC patients.59

Tumour location

According to the most recent findings, the initial location of the tumour within the upper urinary tract (e.g., ureter vs renal pelvis) is no longer accepted as a prognostic factor,11,60,61 contrary to previously published reports (LE: 3).62 It seems there is no longer a prognostic impact for tumour location (i.e., ureteral vs pyelocaliceal tumours) when adjusted for tumour stage.11,63

Lymphovascular invasion

Lymphovascular invasion is present in approximately 20% of UUT-UCCs and an independent predictor of survival. Lymphovascular invasion status should be included in the pathologic report of RNU specimens (LE: 3).64–66 However, only in patients with negative lymph nodes does lymphovascular invasion add prognostic information beyond that obtained with standard features.64

Other factors

Extensive tumour necrosis is an independent predictor of clinical outcomes in patients who undergo RNU. Extensive tumour necrosis can be defined as >10% of the tumour area (LE: 3).67,68

The tumour architecture (e.g., papillary vs sessile) of UUT-UCCs appears to be associated with prognosis after RNU. A sessile growth pattern is associated with worse outcomes (LE: 3).67,68

The presence of concomitant CIS in patients with organ-confined UUT-UCC is associated with a higher risk of recurrent disease and cancer-specific mortality (LE: 3).70 Similar to lower tract urothelial carcinoma, concomitant CIS is an independent predictor of worse outcomes in organ-confined disease.71

Molecular markers

Several research groups are working on upper urinary tract tumour characteristics and carcinogenesis pathways. Specific markers that could aid in the prognosis of UUT-UCCs have been investigated. Microsatellite instabilities (MSIs) are independent molecular markers used for tumour prognosis.72 In addition, MSIs can help detect germ-line mutations, allowing for the detection of possible hereditary cancers.14,16,72

E-cadherin has been shown to be a useful independent marker for prognosis, as have hypoxia-inducible factor (HIF)-1α and telomerase RNA component.73 Furthermore, HIF-1α
appears to be significantly associated with tumour grade and growth pattern, and the telomerase RNA component could possibly be used for UUT-UCCs, regardless of the location of the tumour in the upper urinary tract (LE: 3). The RNU procedure must comply with oncologic principles, which consist of preventing tumour seeding by avoiding entry into the urinary tract during tumour resection. Resection of the distal ureter and its orifice is performed because it is a part of the urinary tract with considerable risk of recurrence. After removal of the proximal part, it is almost impossible to image or approach it by endoscopy during follow-up. Recent publications on survival after nephroureterectomy have concluded that removal of the distal ureter and bladder cuff is beneficial.

**Treatment**

**Localised disease**

**Radical nephroureterectomy.** RNU with excision of the bladder cuff is the gold standard treatment for UUT-UCCs, regardless of the location of the tumour in the upper urinary tract (LE: 3). The RNU procedure must comply with oncologic principles, which consist of preventing tumour seeding by avoiding entry into the urinary tract during tumour resection. Resection of the distal ureter and its orifice is performed because it is a part of the urinary tract with considerable risk of recurrence. After removal of the proximal part, it is almost impossible to image or approach it by endoscopy during follow-up. Recent publications on survival after nephroureterectomy have concluded that removal of the distal ureter and bladder cuff is beneficial.

McDonald et al. presented the pluck technique in 1952, but it was not until 1995 that the usefulness of an endoscopic approach to the distal ureter was really emphasised, and then several other alternative techniques were reconsidered to simplify resection of the distal ureter: stripping, transurethral resection of the intramural ureter, and intussusception techniques. Apart from ureteral stripping, none of these techniques have demonstrated inferiority to excision of the bladder cuff (LE: 3). A delay >45 days between diagnosis and resection of the tumour constitutes a risk for disease progression (LE: 3).

Lymph node dissection associated with RNU is of therapeutic interest and allows for optimal staging of the disease (LE: 3). Lymphadenectomy in pN+ allows for reduction of the tumour mass to guide patients towards adjuvant treatments (LE: 3). However, the anatomic sites of lymphadenectomy have not yet been clearly defined. The number of lymph nodes to be removed depends on the tumour location. No trial so far has shown its direct impact on survival. Lymphadenectomy appears to be unnecessary in cases of T1–T3 UUT-UCCs because it was reported to be retrieved in 2.2% of T1 vs 16% of T2–4 tumours. In addition, authors have described a continuous increase in the probability of lymph node-positive disease related to pT classification. Lastly, lymphadenectomy appears to be a prognostic variable within a model in patients with histologically confirmed node-negative (pN0) disease. However, these data are retrospective; it is not possible to standardise either indication or the extent of lymphadenectomy. Consequently, underreporting of the true rate of node-positive disease is likely.

The safety of laparoscopic RNU has not yet achieved final proof. In early experience, there were reports of retroperitoneal metastatic dissemination and dissemination along the trocar pathway when large tumours were manipulated in a pneumoperitoneal environment.

Recent data, however, show a tendency towards equivalent oncologic results between laparoscopic RNU and open surgery. In addition, the laparoscopic approach appears to be superior to open surgery only with regard to functional outcomes (LE: 3). Only one prospective randomised study of 80 patients did not provide evidence that laparoscopic RNU is inferior to open RNU for non-invasive UUT-UCCs (LE: 2).

Several precautions must be taken when operating with a pneumoperitoneum because it may increase tumour spillage:

1. Entering the urinary tract should be avoided.
2. Direct contact of the instruments with the tumour should be avoided.
3. Laparoscopic RNU must take place in a closed system. Morcellation of the tumour should be avoided, and an endobag is necessary to extract the tumour.
4. The kidney and ureter must be removed en bloc with the bladder cuff.
5. Invasive, large (T3/T4 and/or N+/M+), or multifocal tumours are contraindications for laparoscopic RNU, until proven otherwise.

**Recommendations are listed in Table 3.**

**Conservative surgery.** Conservative surgery for low-risk UUT-UCCs allows for preservation of the upper urinary renal unit while sparing the patient the morbidity associated with open radical surgery. Conservative management of UUT-UCCs can be considered in imperative cases (renal insufficiency, solitary functional kidney) or in elective cases (i.e., when the contralateral kidney is functional) for low-grade, low-stage tumours (LE: 3). The choice of technique depends on technical constraints, the anatomic location of the tumour, and the experience of the surgeon.

**Ureteroscopy.** Endoscopic ablation can be considered in highly selected cases and in these situations:

1. A flexible rather than a rigid ureteroscope, laser generator, and pliers (pluck) for biopsies are available (LE: 3).
2. The patient is informed of the need for closer, more stringent surveillance.
3. A complete resection is advocated.

**Segmental resection.** Segmental ureteral resection with wide margins provides adequate pathologic specimens for definitive staging and grade analysis while also preserving the ipsilateral kidney. Segmental resection is possible for the treatment of low- and high-risk tumours of the distal ureter (LE: 3). It is necessary, however, to ensure that the area of tissue around the tumour is not invaded. Segmental resection of the iliac and lumbar ureter is associated with a failure rate greater than that for the distal pelvic ureter.

Open resection of tumours of the renal pelvis or calices has almost disappeared. Resection of pyelocalyceal tumours is technically difficult, and the recurrence rate is higher than for tumours of the ureter.

**Percutaneous access.** Percutaneous management can be considered for low-grade or non-invasive UUT-UCCs in the renal cavities (LE: 3). This treatment option may
be offered to patients with low-grade tumours in the lower caliceal system that are inaccessible or difficult to manage by ureteroscopy. A theoretical risk of seeding exists in the puncture tract and in perforations that may occur during the procedure. This approach, however, is being progressively abandoned due to enhanced materials and advances in distal-tip deflection of recent ureteroscopes.

Adjuvant topical agents. The instillation of bacillus Calmette–Guérin or mitomycin C in the urinary tract by percutaneous nephrostomy via a three-valve system open at 20 cm (after complete eradication of the tumour), or even through a ureteric stent, is technically feasible after conservative treatment of UUT-UCCs or for the treatment of CIS. The medium-term results are similar to those observed for the treatment of bladder tumours but have not been confirmed in long-term studies (LE: 3). Table 4 reports the recommendations.

Advanced disease

Nephroureterectomy. There are no benefits of RNU in metastatic (M+) disease, although it can be considered a palliative option (LE: 3). Chemotherapy. Because UUT-UCs are urothelial tumours, platinum-based chemotherapy is expected to produce similar results to those seen in bladder cancer. Several platinum-based chemotherapy regimens have been proposed.

Only one study has reported the effect of neoadjuvant chemotherapy in contrast to what has been demonstrated in the bladder. While survival data need to mature and longer follow-up is awaited, current preliminary data provide justification for the sustained support of trials using this strategy in UUT-UCs.

Adjuvant chemotherapy achieves a recurrence-free rate of up to 50% but has minimal impact on survival. Not all the patients receive this treatment because of comorbidities and impaired renal function after radical surgery. Data are currently insufficient to provide any recommendations.

Radiation therapy. Adjuvant radiotherapy may improve local control of the disease. When given in combination with cisplatinum, it may result in a longer disease-free survival and longer overall survival (LE: 3). Radiation therapy appears to be scarcely relevant nowadays both as a unique strategy and associated with chemotherapy as a tumour adjuvant (Fig. 1).

Follow-up

Strict follow-up of UUT-UCC patients after surgical treatment is mandatory to detect metachronous bladder tumours (in all cases), local recurrence, and distant metastases (in the case of invasive tumours).

When RNU is performed, local recurrence is rare, and the risk of distant metastases is directly related to the risk factors listed previously. The reported recurrence rate within the bladder after treatment of a primary UUT-UCC varies considerably from 15% to 50%. Thus the bladder should be observed in all cases. A prior history of bladder cancer and upper tract multifocality are the risk factors most often reported for bladder tumours following UUT-UCs. The surveillance regimen is based on cystoscopy and urinary cytology for at least 5 yr. A bladder recurrence should not be considered a distant recurrence. When conservative treatment is performed, the ipsilateral upper urinary tract requires careful follow-up due to the high risk of recurrence. Despite notable improvements in endourologic technology, the follow-up of patients treated with conservative therapy is difficult, and minimally invasive procedures are often necessary.

Table 3 Guidelines for radical management of urothelial cell carcinoma of the upper urinary tract: radical nephroureterectomy.

<table>
<thead>
<tr>
<th>GR</th>
<th>Indications for RNU for UUT-UCC</th>
<th>Techniques for RNU in UUT-UCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Suspicion of infiltrating UUT-UCC on imaging</td>
<td>Open and laparoscopic access are equivalent in terms of efficacy</td>
</tr>
<tr>
<td>B</td>
<td>High-grade tumour (urothelial cytology)</td>
<td>Bladder cuff removal is imperative</td>
</tr>
<tr>
<td>B</td>
<td>Multifocality (with two functional kidneys)</td>
<td>Several techniques for bladder cuff excision are acceptable except stripping</td>
</tr>
</tbody>
</table>

GR = grade of recommendation; RNU = radical nephroureterectomy; UUT-UCC = urothelial cell carcinoma of the upper urinary tract.

Table 4 Guidelines for conservative management of urothelial cell carcinoma of the upper urinary tract.

<table>
<thead>
<tr>
<th>GR</th>
<th>Indications for conservative management of UUT-UCC</th>
<th>Techniques used in conservative management of UUT-UCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Unifocal tumour</td>
<td>Laser should be used in case of endoscopic treatment</td>
</tr>
<tr>
<td>B</td>
<td>Small tumour</td>
<td>Flexible ureteroscopy is preferable over rigid ureteroscopy</td>
</tr>
<tr>
<td>B</td>
<td>Low-grade tumour (cytology or biopsies)</td>
<td>Open partial resection is an option for pelvic ureteral tumours</td>
</tr>
<tr>
<td>B</td>
<td>No evidence of an infiltrative lesion on</td>
<td>A percutaneous approach remains an option in small low-grade caliceal tumours unsuitable for ureteroscopic treatment</td>
</tr>
</tbody>
</table>

GR = grade of recommendation; MDCTU = multidetector computed tomographic urography; UUT-UCC = urothelial cell carcinoma of the upper urinary tract.

Table 5 lists the recommended follow-up schedules.
**Figure 1** Proposed flowchart for the management of upper urinary tract urothelial cell carcinoma (UUT-UCC). CT = computed tomography; MDCTU = multidetector computed tomographic urography.

**Table 5** Guidelines for follow-up of urothelial cell carcinoma of the upper urinary tract patients after initial treatment.

<table>
<thead>
<tr>
<th>GR</th>
<th>After RNU, over at least 5 yr</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Non-invasive tumour</td>
</tr>
<tr>
<td></td>
<td>Cystoscopy/urinary cytology at 3 mo and then yearly</td>
</tr>
<tr>
<td></td>
<td>MDCTU every year</td>
</tr>
<tr>
<td></td>
<td>Invasive tumour</td>
</tr>
<tr>
<td></td>
<td>Cystoscopy/urinary cytology at 3 mo and then yearly</td>
</tr>
<tr>
<td></td>
<td>MDCTU every 6 mo over 2 yr and then yearly</td>
</tr>
</tbody>
</table>

| After conservative management, over at least 5 yr |
| Urothelial cytology and MDCTU at 3 mo, 6 mo, and then yearly | C |
| Cystoscopy, ureteroscopy and cytology in situ at 3 mo, 6 mo, and then every 6 mo over 2 yr, and then yearly | C |

GR = grade of recommendation; MDCTU = multidetector computed tomographic urography; RNU = radical nephroureterectomy; UUT-UCC = urothelial cell carcinoma of the upper urinary tract.

**Conclusions**

These guidelines contain information for the diagnosis and treatment of individual patients according to a current, standardised approach. When determining the optimal treatment regimen for their patients, physicians must take into account each individual patient’s specific clinical characteristics with regard to renal function including medical comorbidities; tumour location, grade, and stage; and molecular marker status.

**Conflicts of interest**

Morgan Rouprêt had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Rouprêt, Oosterlinck. Acquisition of data: Rouprêt, Zigeuner, Oosterlinck. Analysis and interpretation of data: Rouprêt, Oosterlinck. Drafting of the manuscript: Rouprêt. Critical revision of the manuscript: Rouprêt, Zigeuner, Palou, Celler, Kaasinen, Sylvester, Babjuk, Oosterlinck. Statistical analysis: None. Obtaining funding: None. Administrative, technical, or material support: None. Supervision: None.

Other (specify): None. I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment/affiliation, grants or funding, consultancies, honoraria, stock ownership.
or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Juan Palou is a consultant and honorarium speaker for Sanofi-Pasteur and a consultant, honorarium speaker, and trial participant for General Electric. Andreas Boehler is an honorarium speaker for Sanofi-Aventis, Medac, Bard, and Fresenius. Eero Kaasinen has received research grants from the Pfizer Foundation and for a research group from Pfizer. Richard Sylvester is a consultant for Bioniche, Allergan, and Astra Zeneca, and he was an honorarium speaker for the Kyowa 2008 EAU Satellite Symposium. Marko Babjuk is an honorarium speaker for GE Healthcare and Novartis. Willem Oosterlinck is an honorarium speaker for Organan, Sanofi-Aventis, Novartis, and Pfizer; he participates in trials conducted by Amgen, Astra Zeneca, Novartis, and Astellas; he has received fellowships and travel grants from Astra Zeneca and Sanofi-Aventis and research grants from Astra Zeneca.

References


24. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and


79. Laguna MP, De la Rosette JJ. The endoscopic approach to the distal ureter in nephroureterectomy for upper
European guidelines for the diagnosis and management


107. Thalmann GN, Markwalder R, Walter B, Studer UE. Long-term experience with bacillus Calmette-Guerin therapy of...


